Dapsone
Brand names: Aczone (topical), Dapsone (oral — systemic indications)
Topical dapsone is a gel formulation of the sulfone antibacterial applied to the skin for inflammatory acne vulgaris.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Applied locally it exerts anti-inflammatory and antimicrobial effects, attenuating the neutrophilic inflammation that characterises inflammatory acne lesions.
Prescribing in practice
- A transient yellow-orange skin or hair discolouration can occur where the gel contacts benzoyl peroxide, so the two should not be applied at the same time.
- Systemic absorption is low, so the haematological risks seen with oral dapsone are not generally expected with topical use.
- Confine application to the affected skin and avoid the eyes, lips and mucous membranes.
Monitoring
Routine blood monitoring is not required for topical use; assess the treated skin for irritation and therapeutic response at review.
Counselling the patient
- Apply a thin film to clean, dry affected skin and wash your hands afterwards.
- Do not use benzoyl peroxide products at the same time of day, as together they may temporarily stain skin or hair orange.
- Mild dryness, redness or stinging may occur initially and usually settles.
Evidence & guidelines
Topical dapsone gel has demonstrated efficacy for inflammatory acne in randomised controlled trials underpinning its licence.
Reference: BAD Dermatitis Herpetiformis Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- SIRS Criteria and Sepsis Definition · Sepsis
- Neutrophil-to-Lymphocyte Ratio (NLR) · Inflammatory Markers
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Crohn's Disease Activity Index (CDAI) · Inflammatory Bowel Disease
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD